AccessibilityHelpAbout Us
Hypera logo

Hypera(OTC) HYPMY

Market Cap$3.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-57%
5 Year-14%
1 Year+3%
1 Month+11%
$4.51
+0.05%
+0.00Today
Hypera last closing stock price
MetricPriceDate
Last closeUSD 4.512026-09-18
Hypera stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.69%USD 4.432026-09-11
1 month+10.96%USD 4.062026-08-19
3 month+19.69%USD 3.762026-06-18
Year to date+11.48%USD 4.042025-12-31
1 year+3.01%USD 4.372025-09-18
3 year-33.95%USD 6.822023-09-19
5 year-13.7%USD 5.222021-09-17
Since inception-56.63%USD 10.382010-05-27

Hypera Financials at a Glance

Market Cap

$3.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

R$8.78B

Net Income (TTM)

R$1.74B

EPS (TTM)

$0.50

P/E Ratio

8.93

Dividend

$0.21

Beta (Volatility)

0.45 (Low)

Price

$4.51

Volume

3,032

Open

$4.50

Previous Close

$4.51

Daily Range

$4.45 - $4.53

52-Week Range

$3.71 - $5.50

Estimated Earnings Date

Nov 11, 2026

HYPMY News

View of Salvador City, Bahia, Brazil

Three Top Dividend Stocks in Brazil

Asit Sharma, CPAAug 24, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hypera

Hypera S.A. is a leading pharmaceutical company based in Brazil, specializing in a wide range of prescription medications and consumer health products. The company has established a strong presence in the healthcare sector, offering innovative solutions across various therapeutic areas.

Products and Services
  • Prescription medications under well-known brand names
  • Dermo-cosmetic solutions through Mantecorp Skincare
  • Nutritional and vitamin supplements, including popular labels
Growth Outlook
  • Recent quarterly revenue reached BRL 2.34 billion, indicating strong demand
  • Trailing twelve months (TTM) net income margin stands at 20%, showcasing profitability
  • Market capitalization of approximately USD 3.07 billion reflects investor confidence
Financial Highlights
  • TTM revenue of BRL 8.5 billion, demonstrating consistent growth
  • Quarterly net income of BRL 490 million, up from BRL 341 million last quarter
  • Dividend yield of 4.95%, appealing for income-focused investors
Hypera S.A. has positioned itself as a significant player in the Brazilian pharmaceutical market, with a diverse portfolio that caters to various health needs. The company's focus on innovation and quality has contributed to its robust financial performance, as evidenced by the recent quarterly results. The strong revenue growth and healthy profit margins indicate a solid operational foundation, while the attractive dividend yield may appeal to investors seeking income. With a market capitalization of over USD 3 billion, Hypera S.A. continues to attract attention in the healthcare sector, making it a noteworthy consideration for potential investors.
AI Generated • Sep 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,564

CEO

Breno Toledo Pires de Oliveira, MBA

Website

www.hypera.com.br

Headquarters

São Paulo, SP 05676-120, BR

HYPMY Financials

Key Financial Metrics (TTM)

Gross Margin

58.79%

Operating Margin

28.17%

Net Income Margin

19.80%

Return on Equity

13.10%

Return on Capital

7.95%

Return on Assets

6.04%

Earnings Yield

11.20%

Dividend Yield

4.66%

Payout Ratio

42.97%

Stock Overview

Market Cap

$3.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

703.99M

Volume

3.03K

Avg. Volume

10.58K

Financials (TTM)

Gross Profit

R$5.32B

Operating Income

R$2.48B

EBITDA

R$2.93B

Operating Cash Flow

R$2.41B

Capital Expenditure

-R$507.37M

Free Cash Flow

R$1.90B

Cash & ST Invst.

R$1.58B

Total Debt

R$7.48B

Hypera Performance Analysis

Hypera annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31BRL 1,461,193,21232.8%
20232023-12-31BRL 1,584,554,0728.4%
20242024-12-31BRL 1,380,548,586-12.9%
20252025-12-31BRL 1,378,112,275-0.2%
Hypera sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.4%
Q42025-12-310.4%
Q12026-03-31-11.5%
Q22026-06-3018.0%
Hypera annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31BRL 0.5133.4%
20232023-12-31BRL 0.510.6%
20242024-12-31BRL 0.39-24.6%
20252025-12-31BRL 0.33-13.8%
Hypera sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.5%
Q42025-12-31-1.4%
Q12026-03-31-23.9%
Q22026-06-3029.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

R$2.34B

+8.5%

Gross Profit

R$1.44B

+11.5%

Gross Margin

61.78%

N/A

Market Cap

$3.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$300.06K

N/A

Employees

10,564

N/A

Net Income

R$490.24M

+14.9%

EBITDA

R$755.79M

-1.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

R$1.58B

+31.1%

Total Debt

R$7.48B

-15.6%

Accounts Receivable

R$1.71B

+7.4%

Inventory

R$1.93B

-8.6%

Long Term Debt

R$7.19B

-1.6%

Short Term Debt

R$294.35M

-81.1%

Return on Assets

6.04%

N/A

Return on Invested Capital

9.67%

N/A

Free Cash Flow

R$687.46M

+216.3%

Operating Cash Flow

R$819.20M

+85.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BVNRYBavarian Nordic A/S
$10.61+0.47%
APNHFAspen Pharmacare Holdings Limited
$8.80-1.08%
BVNKFBavarian Nordic A/S
$27.56-15.38%
APNHYAspen Pharmacare Holdings Limited
$9.64+1.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About HYPMY

What is the current price of Hypera?

Hypera is trading at $4.51 per share.

What is the 52-week range for Hypera?

Over the past 52 weeks, Hypera has traded between $3.71 and $5.50.

How much debt does Hypera have?

As of the most recent reporting period, Hypera reported total debt of R$1.48B.

How much cash does Hypera have on hand?

Hypera reported R$304.97M in cash and cash equivalents in its most recent financial results.

What is Hypera’s dividend yield?

Hypera currently has a dividend yield of 4.66%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services